Logo
Skip Navigation LinksHome > Patient Care > Disease and Conditions > Heart Failure > Treatment for Heart failure
Patient care
Disease and Conditions
Drug information
OTC medication
First Aid
Related articles
   
Related Drugs
  Atenolol  
  Benidipine  
  Bisoprolol  
  Candesartan  
  Captopril  
  Clopamide  
  Fosinopril  
  Furosemide  
  Hydrochlorothiazide  
  Indapamide  
  Lisinopril  
  Metolazone  
  Metoprolol  
  Nebivolol  
  Perindopril  
  Ramipril  
  Spironolactone  
  Torsemide  
  Trandolapril  
  Valsartan  
  Xipamide  
Treatment for Heart failure
Size Email this article Print this article
250 Views
Current Rating  
  Login to rate this article

Treatment for Heart failure

The management of heart failure depends on its cause and clinical course, therefore an individualized approach to the treatment is mandatory.

Diuretics and angiotensin converting enzyme (ACE) inhibitors, when combined with nonpharmacological measures, remain the basis of treatment in patients with heart failure.

Pharmacological Management

The pharmacologic treatment tackles four specific management goals:

  • Optimization of the treatment of etiologic conditions=
  • Treatment of fluid retention symptoms
  • Prevention of disease progression
  • Delay in mortality.
The following pharmacological agents are used for symptomatic improvement:
  • ACE inhibitors—enalapril, lisinopril and perindopril
  • Angiotensin receptor blockers (ARBs)—losartan and candesartan
  • Positive inotropes—digoxin
For improvement in survival
  • ACE inhibitors
  • Vasodilatorsoral nitrates in combination with hydralazine

Diuretic therapy is indicated for relief of congestive symptoms. The ACE inhibitors, when added to diuretics, improve the symptoms, exercise tolerance and reduce hospital admission rates in chronic heart failure. The primaryaction of beta-blockers is to counteract the unfavorable effectsof the sympathetic nervous system that are activated during heart failure. The beneficial effects of beta-blockers includeimprovement in the heart remodeling and ejection fraction,the rate of hospitalization, survival, quality of life and the incidenceof sudden death.1

The ARBs should be used only in patients who cannot tolerate ACE inhibitors because of severe cough or angioedema (rapid swelling of the skin, mucosa and submucosal tissues). In patients who remain symptomatic despite diuretic and beta-blocker therapy, treatment with the vasodilator combination of hydralazine and isosorbide dinitratemay be an alternative.7 Once used as first-line therapy, digoxin is now reserved for the control of ventricular rhythm in patients with atrial fibrillation or where adequate control is not achieved with an ACE inhibitor, beta-blocker or a diuretic.


Nonpharmacological Measures

Various nonpharmacological measures to improve symptoms and prognosis of HF include the following:2

  • Aregularly scheduled exercise program, for selected patients.
  • Weight reduction and weight monitoring.
  • Sodium restriction.
  • Fluid restriction, limited to 1.5 L daily.
  • Avoidanceof nonsteroidal antiinflammatory drugs (NSAIDs).
  • Abstain from or limit alcohol consumption.


Revascularization and Surgical Therapy

As CAD is the primary etiology in two-thirdsof all cases of HF, practice guidelines and recent studies recommendcoronary revascularization for patients with HF andCAD.3 Patients with severe CAD and symptomatic left ventricular systolic dysfunction had been observed to have poor outcomes, when treated medically, despite the advances in medical therapy over the past decade.

Revascularization either by coronary artery bypass graft surgery or by percutaneous coronary intervention may improve the long-term outcomes in patients with left ventricular dysfunction and myocardial ischemia, and reduces the risk of sudden death.4         

Next page: Causes of Heart failure 

Written by: Healthplus24 team
Date last updated: April 15, 2012

^ Top of Page
References 
  1. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003; 348(20): 2007–2018.
  2. Smith A, Aylward P, Campbell T, et al. Therapeutic Guidelines: Cardiovascular, 4th edition. North Melbourne: Therapeutic Guidelines; 2003. ISSN 1327–9513.
  3. Tsuyuki RT, Shrive FM, Galbraith PD, Knudtson ML, Graham MM; APPROACH Investigators. Revascularization in patients with heart failure. CMAJ. 2006; 175(4): 361-365.
  4. Baumgartner WA. What's new in cardiac surgery? J Am Coll Surg. 2001; 192: 345–355.
Email this article
Your Name:
Your email Address :
 
Send to this e-mail address:
 
Message:
 
       
  Current Topics  
   
 
 
 
 
 

Patient Care:
Disease and Conditions | Drugs | First Aid | OTC Medication
Health Living: Kids Health | Men's Health | Women's Health | Dental Health | Alternative medicine | Diet and weight loss | Sex and relationship
Tools: Email Reminder | Health Calculators | Find Doctor | Flow charts | know the Signs and Symptoms | Ask your Pharmacist | Ask your Physician | Discussions | Insurance  | Terms of use | Privacy Policy | Advertise with us | Link to our Site | Sitemap | FAQ | Contact Us | About Us | Copy Right | Editorial Policy

This site is sole property of Voyage Marketers Pvt. Ltd. and the material on this site is for information purpose only, and is not substitute for medical advice, Diagnosis or treatment provided by a qualified health care provider.
 
@ 2008-10 Voyage Marketers Pvt. Ltd. All Copy Rights are reserved Best viewed in I.E 7.0 ( 1024 x 768 Pixels )

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

facebook twitter